Roundup trial: Bayer’s glyphosate-cancer legal losses signal public’s flagging trust in regulators

large

Jurors have sided with plaintiffs in all three cases over Bayer AG’s herbicide Roundup to go to trial so far, finding that glyphosate causes cancer and awarding a total of more than $2.2 billion in damages.

Those results underscore a growing skepticism of juries to trust the science conducted by regulators, which, if it continues, could have profound impacts on the ability of companies to defend themselves in product liability cases ….

“Over the past 10 years, jurors have become increasingly skeptical of government regulators ….” said Allan Kanner, a plaintiffs’ attorney with Kanner & Whiteley LLC who handles toxic tort cases.

Monsanto, which was acquired by Bayer AG last year and which makes Roundup, has been accused of covering up the chemical’s health risks.

Despite losing at trial in each of the three cases to go before a jury, the company remains confident that appellate judges will be more willing to side with the company’s toxicology evidence, which includes findings by both federal and international regulators.

But Kanner said that strategy is based on a premise that regulatory experts still hold a deciding influence over jurors. “That model …. is based on a world view among jurors that no longer exists, or is rapidly eroding,” he said.

Read full, original article: Bayer Jury Awards on Roundup Underscore Legal Rift Over Science

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

ChatGPT-Image-May-7-2026-12_32_36-PM
Viewpoint: The state of U.S. vaccine policy? Dismal nationally, but some states are stepping up.
Screenshot-2026-04-22-at-10.46.29-AM
Viewpoint: How to counter science disinformation? Science journalist offers 12 practical tips
Screenshot-2026-04-13-at-1.39.26-PM
Viewpoint: ‘Safer for children?’ Stonyfield yogurt under fire for deceptive organic marketing
the magic of mRNA
Viewpoint: Anti-vax fake ‘turbo cancer’ claims threaten cancer treatment breakthroughs
ChatGPT-Image-May-7-2026-12_16_37-PM-2
Viewpoint: Are cancer rates ‘skyrocketing’ as RFK, Jr. and MAHA claim? The evidence says mostly the opposite
Picture1-1
Cooling the planet with balloons: Could a geoengineering gamble slow global warming?
artificial intelligence brain think illustration md
Viewpoint — Digital gods and human extinction: Will we be the first species ever to design our own descendants?
ChatGPT-Image-May-7-2026-01_23_27-PM-2
Viewpoint: Will AI democratize personalized cancer treatment or fuel medical misinformation?
Defense_Secretary_Ash_Carter_tours_the_Microsoft_Cybercrime_Center_in_Seattle_March_3_2016
How criminals are using AI to target social media users and steal their money and confidential data
Screenshot-2026-04-23-at-11.00.36-AM
Regulators' dilemma: Thalidomide, Metformin, and the cost of getting drug approvals wrong
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.